Delivering quality therapy since 1901

Announcements

 

 

Extraordinary Announcement409<img alt="" src="/en-US/PublishingImages/RG%20eng%20logo.jpg" style="BORDER&#58;0px solid;" />2017.000000000002017-12-04T23:00:00Z12/5/2017 3:57:02 PM60http://rgextend.richter.hu/en-US/investors/announcements/Pages/Forms/AllItems.aspxhtmlFalseaspx
Extraordinary Announcement404<img alt="" src="/en-US/PublishingImages/RG%20eng%20logo.jpg" style="BORDER&#58;0px solid;" />2017.000000000002017-12-03T23:00:00Z12/4/2017 2:20:30 PM64http://rgextend.richter.hu/en-US/investors/announcements/Pages/Forms/AllItems.aspxhtmlFalseaspx
Pharmacovigilance Risk Assessment Committee (PRAC) has initiated a review of Esmya406<img alt="" src="/en-US/PublishingImages/RG%20eng%20logo.jpg" style="BORDER&#58;0px solid;" />2017.00000000000<p>​</p><font face="Arial" size="3"><font face="Arial" size="3"><p align="LEFT">The European Medicines Agency (EMA)</p> <p align="LEFT">Pharmacovigilance Risk Assessment Committee (PRAC) has started a review of drug induced</p> <p align="LEFT">liver injury potentially related to Esmya (ulipristal acetate). The review started due to four</p> <p align="LEFT">reports of serious liver injury, occurred since 2012; the date of the EU marketing authorization,</p> <p>three of which ended in liver transplantation, in patients treated with the medicine.</p></font></font>2017-12-03T23:00:00Z12/5/2017 7:07:34 AM81http://rgextend.richter.hu/en-US/investors/announcements/Pages/Forms/AllItems.aspxhtmlFalseaspx
Extraordinary Announcement399<img alt="" src="/en-US/PublishingImages/RG%20eng%20logo.jpg" style="BORDER&#58;0px solid;" />2017.000000000002017-11-30T23:00:00Z12/1/2017 11:45:48 AM76http://rgextend.richter.hu/en-US/investors/announcements/Pages/Forms/AllItems.aspxhtmlFalseaspx
Composition of share capital and voting rights 402<img alt="" src="/en-US/PublishingImages/RG%20eng%20logo.jpg" style="BORDER&#58;0px solid;" />2017-11-30T23:00:00Z12/1/2017 11:55:46 AM45http://rgextend.richter.hu/en-US/investors/announcements/Pages/Forms/AllItems.aspxhtmlFalseaspx
Extraordinary Announcement396<img alt="" src="/en-US/PublishingImages/RG%20eng%20logo.jpg" style="BORDER&#58;0px solid;" />2017.000000000002017-11-29T23:00:00Z11/30/2017 4:00:38 PM36http://rgextend.richter.hu/en-US/investors/announcements/Pages/Forms/AllItems.aspxhtmlFalseaspx
Extraordinary Announcement393<img alt="" src="/en-US/PublishingImages/RG%20eng%20logo.jpg" style="BORDER&#58;0px solid;" />2017.000000000002017-11-28T23:00:00Z11/29/2017 12:05:20 PM38http://rgextend.richter.hu/en-US/investors/announcements/Pages/Forms/AllItems.aspxhtmlFalseaspx
Extraordinary Announcement391<img alt="" src="/en-US/PublishingImages/RG%20eng%20logo.jpg" style="BORDER&#58;0px solid;" />2017.000000000002017-11-27T23:00:00Z11/28/2017 2:51:32 PM34http://rgextend.richter.hu/en-US/investors/announcements/Pages/Forms/AllItems.aspxhtmlFalseaspx
Extraordinary Announcement355<img alt="" src="/en-US/PublishingImages/RG%20eng%20logo.jpg" style="BORDER&#58;0px solid;" />2017.000000000002017-11-26T23:00:00Z11/27/2017 2:15:07 PM31http://rgextend.richter.hu/en-US/investors/announcements/Pages/Forms/AllItems.aspxhtmlFalseaspx
Extraordinary Announcement354<img alt="" src="/en-US/PublishingImages/RG%20eng%20logo.jpg" style="BORDER&#58;0px solid;" />2017.000000000002017-11-23T23:00:00Z11/24/2017 12:22:05 PM52http://rgextend.richter.hu/en-US/investors/announcements/Pages/Forms/AllItems.aspxhtmlFalseaspx